Supply Lipid-Lowering API Fenofibrate CAS 49562-28-9

• Function: Vitamins and Minerals Deficiency Drug
• Grade Standard: Medicine Grade
• Type: Chemical Reagent
• State: Powder
• Volatile: Not Volatile
• CAS: 49562-28-9
• Model NO.: py0490
• Mf.: C20h21clo4
• Einecs: 256-376-3
• Standard: USP Bp Ep
• Transport Package: 25kg/Drum
• Specification: 99%
• Trademark: puya
• Origin: China
• Production Capacity: 10ton/Year

Product Description

Fenofibrate CAS 49562-28-9

Product Name	Fenofibrate
Synonyms	2-(4-(4-chlorobenzoyl)phenoxy)-2-methyl-propanoicaci1-methylethylester;isopropyl(4'-(p-chlorobenzoyl)-2-phenoxy-2-methyl)propionate;isopropyl2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropionate;lf-178;lipantil;2-[4-(4-CHLOROBENZOYL)PHENOXYL-2-METHYLPROPANOIC ACID 1-METHYLETHYL ESTER;2-[4-(4-CHLOROBENZOYL)PHENOXY]-2-METHYL-PROPANOIC ACID, 1-METHYLETHYL ESTER;2-[4-(4-CHLOROBENZOYL)PHENOXY]-2-METHYLPROPANOIC ACID ISOPROPYL ESTER
CAS	49562-28-9
MF	C20H21ClO4
MW	360.83
EINECS	256-376-3
Product Categories	Active Pharmaceutical Ingredients;Intermediates & Fine Chemicals;Pharmaceuticals;Intracellular receptor;APIS;Aromatics;TRICOR;Cardiovascular APIs;API

Diet therapy for the treatment of adult undesirable effect hypercholesterolemia (IIa type), endogenous hypertriglyceridemia, simple type (IV type) and mixed (IIb and III). Especially applicable to high-density lipoprotein and low-density lipoprotein in patients with moderately elevated in patients with dyslipidemia characterized, and type 2 diabetes mellitus hyperlipidemia


Specification

ITEMS	SPECIFICATION
Appearance	White or almost white crystalline powder
Identification	Meets the requirements
Appearance of Solution	≤GY6
Melting Point	79.0 ~ 82.0
Acidity	Meets the requirements
Related Substances	Meets the requirements
Halogens	≤100ppm
Sulphates	≤100ppm
Heavy Metals	≤20ppm
Loss on Drying	≤0.5%
Sulphated Ash	≤0.1%
Assay	98.5 ~ 101.0%
Standard	EP5

Application

Fenofibrate, marketed as Tricor and under several other brand names, is a drug of the fibrate class. It is mainly used to reduce cholesterol levels in people at risk of cardiovascular disease. Like other fibrates, it reduces both low-density lipoprotein (LDL) and very low density lipoprotein (VLDL) levels, as well as increasing high-density lipoprotein(HDL) levels and reducing triglyceride levels. It is used alone or along with statins in the treatment ofhypercholesterolemia and hypertriglyceridemia.

Fenofibrate is mainly used for primary hypercholesterolemia or mixed dyslipidemia. Fenofibrate appears to decrease the risk of cardiovascular disease and possibly diabetic retinopathy in those with diabetes mellitus, and firstly indicated for the reduction in the progression of diabetic retinopathy in patients with type 2 diabetes and existing diabetic retinopathy in Australia. It also appears to be helpful in decreasing amputations of the lower legs in this same group of people. Fenofibrate also has an off-label use as an added therapy of high blood uric acid levels in people who have gout.